Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium inwardly rectifying channel subfamily J member 12 (KCNJ12)
- Target
- KCNJ12
- Molecular classification
- Ion channel, Potassium channel, Inward rectifier potassium channel (Kir family)
01
Overview
Potassium inwardly rectifying channel subfamily J member 12 (KCNJ12, Kir2.2) is an inwardly rectifying potassium ion channel encoded by the KCNJ12 gene on chromosome 17p11.2. This channel primarily allows potassium ions to flow into cells rather than out, a property termed 'inward rectification,' and is critically involved in stabilizing the resting membrane potential in electrically excitable tissues like heart, muscle, and neurons. Its activity is essential for establishing action potential waveforms, cellular excitability, and normal cardiac electrical conduction. Inward rectification is mainly due to blockage of outward current by internal magnesium, and voltage dependence is regulated by extracellular potassium. Genetic alterations in KCNJ12 have been linked to cardiac, muscular, and neuro-ophthalmologic disorders
- Other names
- ATP-sensitive inward rectifier potassium channel 12Inward rectifier K(+) channel Kir2.2Inward rectifier K(+) channel Kir2.2vIRK-2IRK2KCNJN1hIRKhIRK1hkir2.2xkcnj12xPotassium channel, inwardly rectifying subfamily J member 12Potassium voltage-gated channel subfamily J member 12
02
Mechanism of action
Inhibition or modulation of potassium ion flow through the inward rectifier channel, affecting membrane potential and cellular excitability
03
Biological functions
Regulation of resting membrane potentialModulation of cellular excitabilityEstablishment of action potential waveformPotassium ion transportMuscle contractionRegulation of heart contraction
04
Disease associations
Cardiac arrhythmiaMyotonia congenita, autosomal dominantVitreoretinal degeneration, snowflake typePotential involvement in Smith-Magenis syndrome region
05
Safety considerations
Risk of cardiac arrhythmia through perturbation of IK1 current and resting membrane potential, especially if channel function is impaired or blockedPotential muscle-related side effectsGenetic polymorphisms or disruption can be associated with neurological or cardiac disorders
06
Interacting drugs
Dofetilide (inhibitor)
Beyond the preview
Go deeper on Potassium inwardly rectifying channel subfamily J member 12 (KCNJ12).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Potassium inwardly rectifying channel subfamily J member 12 (KCNJ12).